ManiMNICF 93 Return-on-Tangible-Asset is 13.52% as of Feb. 2026, which is 24% above its 10-year median of 10.87. GuruFocus rates MNICF with a GF Score™ of 93/100 and a GF Value™ of $16.07. The stock has 6 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Mani ranks better than 81.33% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Mani's annualizedNet Income for the quarter that ended in Feb. 2026 was $51.6 Mil. Mani's average total tangible assets for the quarter that ended in Feb. 2026 was $381.8 Mil. Therefore, Mani's annualized Return-on-Tangible-Asset for the quarter that ended in Feb. 2026 was 13.52%.
The historical rank and industry rank for Mani's Return-on-Tangible-Asset or its related term are showing as below:
MNICF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 8.26 Med: 10.87 Max: 16.13
Current: 9.72
During the past 13 years, Mani's highest Return-on-Tangible-Asset was 16.13%. The lowest was 8.26%. And the median was 10.87%.
MNICF's Return-on-Tangible-Asset is ranked better than 81.33% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.57
vs MNICF: 9.72
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Mani Return-on-Tangible-Asset Related Terms
Mani Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Mani's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MNICF vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Mani's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mani Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mani's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Mani's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Feb. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.52% mean?
Mani (MNICF) has a Return-on-Tangible-Asset of 13.52% as of Feb. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mani and its competitors. This is 24% above median its historical median of 10.87. Over the past decade, Mani's Return-on-Tangible-Asset has ranged from 8.26 to 16.13. According to the industry distribution chart, Mani ranks #160 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 18.7%.
Is Mani's Return-on-Tangible-Asset too high?
Mani's current Return-on-Tangible-Asset of 13.52% is 24% above median its 10-year median of 10.87. Over the past 10 years, this metric has ranged from a low of 8.26 to a high of 16.13. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.57. Mani's value of 13.52% is 2271.9% above this industry median. Based on the distribution chart, Mani ranks #160 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Mani has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Mani's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Mani ranks #160 out of 857 companies for Return-on-Tangible-Asset. This places Mani in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.57. Mani's value of 13.52% is 2271.9% above this benchmark. Historically, Mani's own Return-on-Tangible-Asset has ranged from 8.26 to 16.13 over the past decade. While the company's 10-year median is 10.87 vs. the industry median of 0.57, Mani has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.57, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mani's current Return-on-Tangible-Asset of 13.52% is 2271.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mani and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mani's current Return-on-Tangible-Asset is 13.52%, which is 24% above median its own 10-year median of 10.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mani stock overvalued right now?
Mani (MNICF) has a current Return-on-Tangible-Asset of 13.52%. The stock's GF Value™ is $16.07, compared to a current price of $12.82 — trading 20.2% below its estimated fair value. The current Return-on-Tangible-Asset is 13.52%, which is 24% above median its 10-year median of 10.87 and 2271.9% above the Medical Devices & Instruments industry median of 0.57. Mani's overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Mani (MNICF), the current Return-on-Tangible-Asset is 13.52% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mani (MNICF) Overvalued in 2026?
Based on GuruFocus' analysis, Mani stock appears to be undervalued.
The current stock price of $12.82 is trading 20.2% below its estimated GF Value™ of $16.07.
Key valuation signals for MNICF:
Return-on-Tangible-Asset: 13.52% (24% above median its 10-year median of 10.87)
GF Value™: $16.07 vs. price of $12.82 (20.2% below fair value)
Industry Position: 2271.9% above the Medical Devices & Instruments median (#160 of 857)
No single metric tells the full story. See the MNICF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mani Inc manufactures medical devices and dental instruments. It sells products in four categories: surgical instruments, ophthalmic instruments, suture needles, and dental instruments. Mani's surgical products include instruments such as staplers, vessel knives, and bone saws. Its ophthalmic instruments include a range of knives used during eye surgery and ophthalmic sutures. Mani's suture needles business includes a variety of taper point and cutting eyeless needles, which require suture attachment and sterilization by the customer, as well as stainless-steel eyed needles. The firm's dental instruments include endodontic instruments and accessories, root canal equipment, and finishing and polishing instruments.
93GF Score
Get the complete analysis for MNICF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNICF has been successfully added to your 
